Balaxi Pharma
Balaxi Pharma Q4 FY26: Revenue ₹70.71 Cr, PAT ₹0.61 Cr
Q4 FY26 investor presentation: what the company reported on revenue, margins and projects.
Based on Balaxi Pharma's Q4 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Q4 FY26 EBITDA: ₹3.04 crore, down 72% YoY from ₹10.86 crore in Q4 FY25 - Q4 FY26 EBITDA Margin: 4.3%, down 994 bps YoY from 14.2% in Q4 FY25 - Q4 FY26 Profit After Tax (PAT): ₹0.61 crore
From Balaxi Pharma's Q4 FY26 earnings-call transcript · updated 16 Oct 2026.
Revenue & Sales Performance
- Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22).
- FY26 consolidated revenue: ₹270.17 crore, down 7.7% YoY from ₹292.56 crore in FY25 (Page 20).
- Decline in revenue partly attributed to extended working capital cycle in the institutional business, especially Angola (Page 19).
- LATAM region delivered 11% YoY revenue growth to ₹111.29 crore in FY26 (Page 19).
- No explicit volume figures provided in the presentation.
2 more points from Balaxi Pharma's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Balaxi Pharma said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Balaxi has commissioned its first pharmaceutical formulation manufacturing plant at a Pharma SEZ near Hyderabad, focused on General Oral Solid Dosage (OSD) formulations for Latin America and Africa.
- Plant qualification and validation are complete; the facility received its Manufacturing Licence as of FY26.
- The plant enables backward integration of the supply chain, greater product efficacy, improved regulatory processes, and reduced time to market.
- This facility is expected to open new revenue streams, support margin expansion, and strengthen supply chain reliability over the medium term.
- No specific capex amount or detailed capacity expansion figures are provided in the presentation.
2 more points from Balaxi Pharma's call on capex
Pro opens every point from 15K+ earnings calls
Fundraising & Capital Structure
See what Balaxi Pharma said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Balaxi Pharma — Quarterly revenue & net profit
Q4 FY26 figures are not in this chart yet. Latest shown: Dec 2025 (Q3 FY26). The Q4 FY26 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q3 FY26): revenue ₹73 Cr, net profit ₹0 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Balaxi Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Accretion Pha. (Q4 FY26)
45.89 crore, up 18.24% YoY (Page 28). Key investor presentation takeaways from Accretion Pharmaceuticals Ltd's Q4 FY26 investor presentation — and how it ranks
- Gujarat Themis Biosyn Ltd (Q4 FY26)
. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q4 FY26 investor presentation — and how it ranks against sector peers.
- Aptus Pharma (Q4 FY26)
The investor presentation reports quarterly revenue of ₹40.36 crore for Q4 FY2026. Key concall takeaways from Aptus Pharma Ltd's Q4 FY26 earnings call — and…
- Morepen Labs. (Q4 FY26)
472 crore, up 22% year-on-year (YoY) from Rs. Key concall takeaways from Morepen Laboratories Ltd's Q4 FY26 earnings call — and how it ranks against sector…
Arthneeti Pro · Annual
Balaxi Pharma and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Balaxi Pharma Q4 FY26 results?
Q4 FY26 consolidated revenue: ₹70.71 crore, down 7.3% YoY from ₹76.27 crore in Q4 FY25 (Page 22). Q4 FY26 EBITDA: ₹3.04 crore, down 72% YoY from ₹10.86 crore in Q4 FY25 - Q4 FY26 EBITDA Margin: 4.3%, down 994 bps YoY from 14.2% in Q4 FY25 - Q4 FY26 Profit After Tax (PAT): ₹0.61 crore
What is Balaxi Pharma share price analysis?
Balaxi Pharma currently shows a neutral. The stock trades at a P/E of 50.2 with a market cap of ₹122 Cr. Investors should review the full earnings analysis for detailed insights.
Is Balaxi Pharma planning capital expenditure?
Balaxi has commissioned its first pharmaceutical formulation manufacturing plant at a Pharma SEZ near Hyderabad, focused on General Oral Solid Dosage (OSD) formulations for Latin America and Africa.
Keep Balaxi Pharma on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.